Scarica l'app Stockscreener
54.08
2.31%
-1.28
Dopo l'orario di chiusura:
54.04
-0.04
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$55.36
Aprire:
$54.82
Volume 24 ore:
1.37M
Relative Volume:
1.28
Capitalizzazione di mercato:
$3.77B
Reddito:
-
Utile/perdita netta:
$-237.22M
Rapporto P/E:
-14.31
EPS:
-3.78
Flusso di cassa netto:
$-212.64M
1 W Prestazione:
+106.57%
1M Prestazione:
+94.39%
6M Prestazione:
+102.32%
1 anno Prestazione:
+150.25%
Intervallo 1D:
$52.89
$55.88
Intervallo di 1 settimana:
$48.47
$58.40
Portata 52W:
$15.32
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.08 | 3.77B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares - MarketBeat
UBS Group Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - MarketBeat
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Akero Therapeutics chief development officer sells shares worth $3.01 million - Investing.com India
Akero Therapeutics chief development officer sells shares worth $3.01 million By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $2.73 million in stock - Investing.com India
Akero Therapeutics chief development officer sells $2.73 million in stock By Investing.com - Investing.com Canada
Why did Akero (AKRO) stock soar 110% on Monday? - MSN
Akero Therapeutics price target raised to $73 from $56 at Canaccord - MSN
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 31,250 Shares of Stock - MarketBeat
Akero raised to Buy at Bank of America after liver drug data - MSN
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
Akero stock raised to Buy at Bank of America (AKRO:NASDAQ) - Seeking Alpha
Akero Therapeutic prices upsized stock offering of $350M - MSN
Akero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst Upgrade - MarketBeat
Akero Therapeutics senior VP sells $285,150 in stock - MSN
Akero Therapeutics shares soar on positive study results - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Raised to Buy at Bank of America - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock - MSN
Akero Therapeutics senior VP sells $285,150 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics Stock Doubles on Liver Data - MSN
Akero Therapeutics announces proposed public offering of common stock - MSN
Akero Therapeutics' chief scientific officer sells $1.74 million in stock By Investing.com - Investing.com UK
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock By Investing.com - Investing.com UK
Jefferies raises Akero Therapeutics price target to $75 - MSN
MASH momentum prompts $250 million raise for 89bio - The Pharma Letter
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study - MSN
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study - MSN
What is HC Wainwright's Forecast for AKRO FY2029 Earnings? - MarketBeat
Morgan Stanley lifts Akero Therapeutics stock to $96 - MSN
Morgan Stanley Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $96.00 - MarketBeat
AKRO stock hits 52-week high, soaring to $56.86 - MSN
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Akero's Massive $350M Capital Raise Signals Major Development Push in NASH Treatment - StockTitan
Canaccord raises Akero Therapeutics target to $73 - MSN
Akero: Reversal Of Cirrhosis With EFX Is A "First" In F4 MASH Patients (NASDAQ:AKRO) - Seeking Alpha
Akero Therapeutics (NASDAQ:AKRO) Given New $96.00 Price Target at Morgan Stanley - MarketBeat
Some Good MASH/NASH News From Akero Therapeutics (AKRO) - Seeking Alpha
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Akero Therapeutics reports breakthrough in MASH cirrhosis study By Investing.com - Investing.com Canada
Akero’s cirrhosis treatment shows promise in Phase IIb study - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Analyst Upgrade - MarketBeat
Akero Therapeutics succeeds with MASH liver treatment at phase 2 - BioPharma-Reporter.com
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday - Benzinga
Citi raises Akero Therapeutics stock target to $80 on EFX data - MSN
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):